Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Launches Multidisciplinary Synthetic Bio, Big Data Initiatives

NEW YORK (GenomeWeb News) – The University of Cambridge said today it has launched new multidisciplinary, collaborative research programs focused on synthetic biology and big data, as well as cardiovascular disease and public policy.

The university has added the four new subject areas into its Strategic Research Initiative program, which brings together academics from different disciplines to harness their expertise and make a “real-world impact,” Cambridge said.

Professor Lynn Gladden, pro-vice-chancellor for research at Cambridge, said in a statement that these strategic interdisciplinary initiatives “will help to increase our national and international impact, and make our research more visible to funding agencies, charities, industry, and donors.”

Cambridge said it launched the synthetic biology initiative because it is “one of the fastest-growing scientific and technological arenas,” and noted that the school has already “played a key role in advances in bioengineering, computational modeling, and development of standards and protocols.”

The synthetic biology initiative at Cambridge is very much in tune with a national push in this area. The UK government has invested heavily in synthetic biology programs over the past year under a long-term strategic effort to build up the national infrastructure and encourage new business ventures in this field. These investments have included $15 million in funding for a synthetic biology research center at Imperial College, London, $16 million to support new synthetic biology startups, and $6 million for competitive grants for businesses to develop new synthetic biology technologies, among others.

The big data initiative will focus on addressing the implications of the use of massive amounts of data that are being generated from new technologies, as well as the ethical, legal, and political implications of working with such large data sets.

Cambridge said cardiovascular disease research is a major source of the university’s funding, and that this initiative will bring together experts from across disciplines to improve the management, treatment, and prevention of this illness.

The public policy initiative will link investigators from the humanities and the sciences to study the policy process and the impacts that new technologies can have on policy decisions.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.